文献速递糖尿病肥胖与代谢综合征

达格列净减少2型糖尿病患者肝脏脂肪但不影响组织胰岛素敏感性

The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
PubMed 文献 · Diabetes Care · 2019-03-18

这项随机双盲安慰剂对照研究纳入32例2型糖尿病患者,每日10 mg达格列净或安慰剂治疗8周。达格列净改善血糖控制(HbA1c安慰剂校正变化-0.39%,P<0.01),但全身葡萄糖摄取未增加(P=0.90),组织特异性胰岛素敏感性无变化;肝脏PDFF、肝脏体积、内脏脂肪体积、IL-6和NT-proBNP显著下降。

要点

  • 达格列净8周改善血糖控制但未增加全身葡萄糖摄取。
  • 骨骼肌、肝脏、心肌及脂肪组织胰岛素敏感性均无变化。
  • 肝脏脂肪含量和内脏脂肪体积显著下降。

核心结论

  • 8周达格列净治疗减少肥胖2型糖尿病患者肝脏PDFF和内脏脂肪体积,改善血糖控制,但对组织水平胰岛素敏感性无影响。

研究设计与样本

  • 随机、双盲、平行组、安慰剂对照研究,纳入32例2型糖尿病患者,按1:1随机接受每日10 mg达格列净或安慰剂治疗8周。

主要发现

  • HbA1c安慰剂校正变化为-0.39%(P<0.01),但全身葡萄糖摄取未增加(P=0.90)。
  • 骨骼肌、肝脏、心肌及白色和棕色脂肪组织的胰岛素刺激葡萄糖摄取均无变化,内源性葡萄糖生成未受影响。
  • 肝脏PDFF安慰剂校正下降-3.74%(P<0.01),肝脏体积下降-0.10 L(P<0.05),内脏脂肪体积下降-0.35 L(P<0.01)。
  • IL-6下降-1.87 pg/mL(P<0.05),NT-proBNP下降-96 ng/L(P=0.03)。

临床怎么用

  • 达格列净可改善2型糖尿病患者的血糖和肝脏脂肪沉积,但不应期望通过短期治疗直接改善组织胰岛素敏感性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to investigate tissue-specific effects of dapagliflozin on insulin sensitivity and liver and body fat in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: This randomized, double-blind, parallel group, placebo-controlled study recruited 32 patients with type 2 diabetes. Enrolled patients were to have HbA1c 6.5-10.5% (48-91 mmol/mol) and ≥3 months of stable treatment with metformin, dipeptidyl peptidase 4 inhibitor, or their combination. Patients were randomized 1:1 to receive 10 mg dapagliflozin or placebo daily for 8 weeks. Before and after the intervention, tissue insulin sensitivity was measured using [18F]-fluorodeoxyglucose and positron emission tomography during hyperinsulinemic-euglycemic clamp. Liver proton density fat fraction (PDFF) and adipose tissue volumes were assessed using MRI, and blood biomarkers were analyzed. RESULTS: After 8 weeks, glycemic control was improved by dapagliflozin (placebo-corrected change in HbA1c -0.39%, P < 0.01), but whole-body glucose uptake was not increased (P = 0.90). Tissue-specific insulin-stimulated glucose uptake did not change in skeletal muscle, liver, myocardium, or white and brown adipose tissue, and endogenous glucose production remained unaffected. However, there were significant placebo-corrected decreases in liver PDFF (-3.74%, P < 0.01), liver volume (-0.10 L, P < 0.05), visceral adipose tissue volume (-0.35 L, P < 0.01), interleukin-6 (-1.87 pg/mL, P < 0.05), and N-terminal prohormone of brain natriuretic peptide (-96 ng/L, P = 0.03). CONCLUSIONS: In this study, 8 weeks of treatment with dapagliflozin reduced liver PDFF and the volume of visceral adipose tissue in obese patients with type 2 diabetes. Although glycemic control was improved, no effect on tissue-level insulin sensitivity was observed.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Latva-Rasku A, Honka MJ, Kullberg J, et al. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients. Diabetes Care. 2019. PMID: 30885955. doi:10.2337/dc18-1569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。